917369-31-4

Basic information

• Product Name: N-(4-Methoxyphenyl)-N,2-dimethyl-4-quinazolinamine hydrochloride
• Synonyms: N-(4-Methoxyphenyl)-N,2-dimethyl-4-quinazolinamine hydrochloride;Verubulin hydrochloride;Azixa;MPC 6827 hydrochloride;N-(4-methoxyphenyl)-N,2-dimethylquinazolin-4-amine hydrochloride;EP-128495
• CAS NO: 917369-31-4
• Molecular Formula: C17H17N3O.HCl
• Molecular Weight: 315.79732
• Mol File: 917369-31-4.mol
• Article Data: 0

Chemical Properties

• Appearance: /
• Solubility: ≥10.55 mg/mL in DMSO; ≥28.1 mg/mL in EtOH; ≥5 mg/mL in H2O
• CAS DataBase Reference: N-(4-Methoxyphenyl)-N,2-dimethyl-4-quinazolinamine hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-Methoxyphenyl)-N,2-dimethyl-4-quinazolinamine hydrochloride(917369-31-4)
• EPA Substance Registry System: N-(4-Methoxyphenyl)-N,2-dimethyl-4-quinazolinamine hydrochloride(917369-31-4)

Safety Data

• Hazardous Substances Data: 917369-31-4(Hazardous Substances Data)

Usage

Uses

MPC 6827 Hydrochloride is a microtubule destabilizing agent which may be used in the treatment of patients with cancer.

Biological Activity

mpc-6827 (azixa) is a small-molecule microtubule-destabilizing agent that binds to the same (or nearby) sites on β-tubulin as colchicine.[1]tubulin is a heterodimer consisting of an αand βmonomer, it can be covalently labeled with [3h] colchicine by near uv irradiation. most of the label appears in β tubulin. colchicine binds to tubulin with a stoichiometry of one and inhibits microtubule assembly substoichiometrically. colchicine binding to tubulin exhibits pseudoirreversible kinetics; it displays a fast step followed by a slow step involving conformational changes of both ligand and tubulin. the tubulin, in turn, promotes fluorescence characteristic of the tropolone moiety of colchicine. [2]mpc-6827 is a small-molecule microtubule-destabilizing agent that causes mitotic arrest and cell death. mpc-6827 interfere with microtubule dynamics, leading to arrest of dividing cells in the g2-m phase of the cell cycle, which eventually results in apoptotic cell death.[1]

in vivo

mpc-6827 significantly inhibits the growth of various subcutaneously implanted tumor lines. mpc-6827 has also been shown to be a vascular-disrupting agent (vda) in a human ovarian carcinoma xenograft model. it also has shown synergism with carboplatin in a mouse xenograft model. furthermore, mpc-6827 has been shown to inhibit the growth of human glioblastoma tumor cell line (d-54) implanted intracranially in athymic nude mice. [1]

references

[1] tsimberidou am1, akerley w, schabel mc, etal. , phase i